CGON
CG Oncology, Inc.
67.20$
-2.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -120,511.1% | -1,606,100.0% | -4,917.2% | -14,522.5% | -37,020.9% | -4,531.1% | -56,301.9% | – | -2,334.6% | -1,559.7% | -5,257.9% | -4,011.6% | -2,865.6% | |
| 55.6% | -500.0% | 0.8% | 6.3% | 48.8% | 0.0% | 46.2% | – | 25.0% | 36.6% | 77.7% | 73.5% | 47.5% | |
| 4,377.8% | 77,800.0% | 286.8% | 2,023.4% | 6,160.5% | 1,094.3% | 9,905.8% | – | 440.0% | 309.5% | 597.8% | 1,238.9% | 567.2% | |
| 2,166.7% | 216,200.0% | -1,587.7% | 2,709.0% | 7,911.6% | 1,073.7% | 901.9% | – | -172.4% | -171.5% | -533.6% | 1,243.1% | 28.1% | |
| 66.7% | 0.0% | 2.3% | 12.6% | 2.3% | 45.8% | 30.8% | – | 5.8% | 0.3% | 28.1% | 40.4% | 14.1% | |
| -1,808,844.4% | 1,694,300.0% | -58,118.0% | -32,639.6% | 74,430.2% | 2,391.4% | -359,171.2% | – | 903.1% | -3,251.7% | -30,918.3% | 2,629.9% | -5,858.7% | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | – | 0.0% | 0.0% | – | – | – | |
| 1,176,400.0% | -288,900.0% | 76,116.8% | 36.0% | 5,039.5% | 48,994.3% | 865.4% | – | 3,263.5% | 4,266.4% | 36,287.9% | 166.1% | 8,804.7% | |
| -752,955.6% | -200,700.0% | 13,081.7% | -47,126.1% | 42,448.8% | 46,854.6% | -414,607.7% | – | 1,832.0% | -545.0% | 111.7% | -1,215.6% | 80.5% | |
| -120,444.4% | -1,606,100.0% | -4,919.5% | -14,535.1% | -37,018.6% | -4,577.0% | -56,332.7% | – | -2,340.4% | -1,560.0% | -5,286.0% | -4,052.0% | -2,879.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.